Induction of granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I-MEK-ERK pathway

Mio Kawaguchi, Fumio Kokubu, Miho Odaka, Shin Watanabe, Shintaro Suzuki, Koushi Ieki, Satoshi Matsukura, Masatsugu Kurokawa, Mitsuru Adachi, Shau Ku Huang

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background ML-1 (IL-17F) is a recently discovered cytokine, and its function remains elusive. GM-CSF is a crucial cytokine for the maturation of various cell types and regulates allergic airway inflammation. Objective The functional effect of ML-1 in the expression of GM-CSF was investigated. Methods The levels of gene and protein expression in normal human bronchial epithelial cells (NHBEs) in the presence or absence of various kinase inhibitors or, in some cases, of a Raf1 dominant-negative mutant were determined by RT-PCR and ELISA, respectively. Western blotting was performed to investigate kinase activation. Results The results showed first that ML-1 induces, in a time-dependent and dose-dependent manner, the gene and protein expression for GM-CSF NHBEs, which are associated with activation of Raf1 and MAP kinase kinase (MEK) kinases. Selective MEK inhibitors, PD98059 and U0126, and Raf1 kinase inhibitor I significantly inhibited ML-1-induced GM-CSF production. Furthermore, overexpression of Raf1 dominant-negative mutants inhibited IL-17F-induced GMCSF expression. The combination of PD98059 and Raf1 kinase inhibitor I completely blocked GM-CSF production, whereas 2 protein kinase C inhibitors, Ro-31-7549 and GF109203X, and a phosphatidylinositol 3-kinase inhibitor, LY294002, showed no inhibitory effect. Conclusion These findings suggest that ML-1 induces GM-CSF expression through the activation of the Raf1-MEK-extracellular signal-regulated kinase 1/2 pathway.

Original languageEnglish
Pages (from-to)444-450
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume114
Issue number2
DOIs
Publication statusPublished - Aug 1 2004
Externally publishedYes

Fingerprint

Interleukin-17
MAP Kinase Signaling System
Mitogen-Activated Protein Kinase Kinases
Granulocyte-Macrophage Colony-Stimulating Factor
Phosphotransferases
Epithelial Cells
Phosphatidylinositol 3-Kinase
Cytokines
MAP Kinase Kinase Kinases
Gene Expression
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Mitogen-Activated Protein Kinase 3
Protein C Inhibitor
Mitogen-Activated Protein Kinase 1
Protein Kinase Inhibitors
Protein Kinase C
Proteins
Western Blotting
Enzyme-Linked Immunosorbent Assay
Inflammation

Keywords

  • Bronchial epithelial cells
  • Dimethyl sulfoxide
  • DMSO
  • ERK
  • ERK1/2
  • Extracellular signal-regulated kinase
  • GM-CSF
  • MAP kinase
  • MAP kinase kinase
  • MEK
  • NF-κB
  • NHBE
  • Normal human bronchial epithelial cell
  • Nuclear factor κB
  • PI3K
  • Raf1

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Induction of granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I-MEK-ERK pathway. / Kawaguchi, Mio; Kokubu, Fumio; Odaka, Miho; Watanabe, Shin; Suzuki, Shintaro; Ieki, Koushi; Matsukura, Satoshi; Kurokawa, Masatsugu; Adachi, Mitsuru; Huang, Shau Ku.

In: Journal of Allergy and Clinical Immunology, Vol. 114, No. 2, 01.08.2004, p. 444-450.

Research output: Contribution to journalArticle

Kawaguchi, M, Kokubu, F, Odaka, M, Watanabe, S, Suzuki, S, Ieki, K, Matsukura, S, Kurokawa, M, Adachi, M & Huang, SK 2004, 'Induction of granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I-MEK-ERK pathway', Journal of Allergy and Clinical Immunology, vol. 114, no. 2, pp. 444-450. https://doi.org/10.1016/j.jaci.2004.03.047
Kawaguchi, Mio ; Kokubu, Fumio ; Odaka, Miho ; Watanabe, Shin ; Suzuki, Shintaro ; Ieki, Koushi ; Matsukura, Satoshi ; Kurokawa, Masatsugu ; Adachi, Mitsuru ; Huang, Shau Ku. / Induction of granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I-MEK-ERK pathway. In: Journal of Allergy and Clinical Immunology. 2004 ; Vol. 114, No. 2. pp. 444-450.
@article{219e467897d84bbd859199fc98078dd0,
title = "Induction of granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I-MEK-ERK pathway",
abstract = "Background ML-1 (IL-17F) is a recently discovered cytokine, and its function remains elusive. GM-CSF is a crucial cytokine for the maturation of various cell types and regulates allergic airway inflammation. Objective The functional effect of ML-1 in the expression of GM-CSF was investigated. Methods The levels of gene and protein expression in normal human bronchial epithelial cells (NHBEs) in the presence or absence of various kinase inhibitors or, in some cases, of a Raf1 dominant-negative mutant were determined by RT-PCR and ELISA, respectively. Western blotting was performed to investigate kinase activation. Results The results showed first that ML-1 induces, in a time-dependent and dose-dependent manner, the gene and protein expression for GM-CSF NHBEs, which are associated with activation of Raf1 and MAP kinase kinase (MEK) kinases. Selective MEK inhibitors, PD98059 and U0126, and Raf1 kinase inhibitor I significantly inhibited ML-1-induced GM-CSF production. Furthermore, overexpression of Raf1 dominant-negative mutants inhibited IL-17F-induced GMCSF expression. The combination of PD98059 and Raf1 kinase inhibitor I completely blocked GM-CSF production, whereas 2 protein kinase C inhibitors, Ro-31-7549 and GF109203X, and a phosphatidylinositol 3-kinase inhibitor, LY294002, showed no inhibitory effect. Conclusion These findings suggest that ML-1 induces GM-CSF expression through the activation of the Raf1-MEK-extracellular signal-regulated kinase 1/2 pathway.",
keywords = "Bronchial epithelial cells, Dimethyl sulfoxide, DMSO, ERK, ERK1/2, Extracellular signal-regulated kinase, GM-CSF, MAP kinase, MAP kinase kinase, MEK, NF-κB, NHBE, Normal human bronchial epithelial cell, Nuclear factor κB, PI3K, Raf1",
author = "Mio Kawaguchi and Fumio Kokubu and Miho Odaka and Shin Watanabe and Shintaro Suzuki and Koushi Ieki and Satoshi Matsukura and Masatsugu Kurokawa and Mitsuru Adachi and Huang, {Shau Ku}",
year = "2004",
month = "8",
day = "1",
doi = "10.1016/j.jaci.2004.03.047",
language = "English",
volume = "114",
pages = "444--450",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Induction of granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I-MEK-ERK pathway

AU - Kawaguchi, Mio

AU - Kokubu, Fumio

AU - Odaka, Miho

AU - Watanabe, Shin

AU - Suzuki, Shintaro

AU - Ieki, Koushi

AU - Matsukura, Satoshi

AU - Kurokawa, Masatsugu

AU - Adachi, Mitsuru

AU - Huang, Shau Ku

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Background ML-1 (IL-17F) is a recently discovered cytokine, and its function remains elusive. GM-CSF is a crucial cytokine for the maturation of various cell types and regulates allergic airway inflammation. Objective The functional effect of ML-1 in the expression of GM-CSF was investigated. Methods The levels of gene and protein expression in normal human bronchial epithelial cells (NHBEs) in the presence or absence of various kinase inhibitors or, in some cases, of a Raf1 dominant-negative mutant were determined by RT-PCR and ELISA, respectively. Western blotting was performed to investigate kinase activation. Results The results showed first that ML-1 induces, in a time-dependent and dose-dependent manner, the gene and protein expression for GM-CSF NHBEs, which are associated with activation of Raf1 and MAP kinase kinase (MEK) kinases. Selective MEK inhibitors, PD98059 and U0126, and Raf1 kinase inhibitor I significantly inhibited ML-1-induced GM-CSF production. Furthermore, overexpression of Raf1 dominant-negative mutants inhibited IL-17F-induced GMCSF expression. The combination of PD98059 and Raf1 kinase inhibitor I completely blocked GM-CSF production, whereas 2 protein kinase C inhibitors, Ro-31-7549 and GF109203X, and a phosphatidylinositol 3-kinase inhibitor, LY294002, showed no inhibitory effect. Conclusion These findings suggest that ML-1 induces GM-CSF expression through the activation of the Raf1-MEK-extracellular signal-regulated kinase 1/2 pathway.

AB - Background ML-1 (IL-17F) is a recently discovered cytokine, and its function remains elusive. GM-CSF is a crucial cytokine for the maturation of various cell types and regulates allergic airway inflammation. Objective The functional effect of ML-1 in the expression of GM-CSF was investigated. Methods The levels of gene and protein expression in normal human bronchial epithelial cells (NHBEs) in the presence or absence of various kinase inhibitors or, in some cases, of a Raf1 dominant-negative mutant were determined by RT-PCR and ELISA, respectively. Western blotting was performed to investigate kinase activation. Results The results showed first that ML-1 induces, in a time-dependent and dose-dependent manner, the gene and protein expression for GM-CSF NHBEs, which are associated with activation of Raf1 and MAP kinase kinase (MEK) kinases. Selective MEK inhibitors, PD98059 and U0126, and Raf1 kinase inhibitor I significantly inhibited ML-1-induced GM-CSF production. Furthermore, overexpression of Raf1 dominant-negative mutants inhibited IL-17F-induced GMCSF expression. The combination of PD98059 and Raf1 kinase inhibitor I completely blocked GM-CSF production, whereas 2 protein kinase C inhibitors, Ro-31-7549 and GF109203X, and a phosphatidylinositol 3-kinase inhibitor, LY294002, showed no inhibitory effect. Conclusion These findings suggest that ML-1 induces GM-CSF expression through the activation of the Raf1-MEK-extracellular signal-regulated kinase 1/2 pathway.

KW - Bronchial epithelial cells

KW - Dimethyl sulfoxide

KW - DMSO

KW - ERK

KW - ERK1/2

KW - Extracellular signal-regulated kinase

KW - GM-CSF

KW - MAP kinase

KW - MAP kinase kinase

KW - MEK

KW - NF-κB

KW - NHBE

KW - Normal human bronchial epithelial cell

KW - Nuclear factor κB

KW - PI3K

KW - Raf1

UR - http://www.scopus.com/inward/record.url?scp=4344609710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344609710&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2004.03.047

DO - 10.1016/j.jaci.2004.03.047

M3 - Article

C2 - 15316530

AN - SCOPUS:4344609710

VL - 114

SP - 444

EP - 450

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 2

ER -